Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172309 | 1.00 | ADORA3 (0.34) | ADORA3ADORA2AADORA1GSK3BTNKS2 | |
| SCHEMBL4185613 | 0.80 | KMT2A (0.43) | TNKS2 | |
| SCHEMBL4185609 | 0.80 | KMT2A (0.43) | TNKS2 | |
| SCHEMBL4185620 | 0.80 | KMT2A (0.43) | TNKS2 | |
| SCHEMBL4179962 | 0.79 | — | — | |
| SCHEMBL4179958 | 0.79 | — | — | |
| SCHEMBL4179952 | 0.79 | — | — | |
| SCHEMBL2759101 | 0.79 | TNKS2 (0.36) | ADORA3ADORA2AADORA1GSK3BTNKS2 | |
| SCHEMBL13417830 | 0.76 | ADORA3 (0.38) | ADORA3ADORA2AADORA1 | |
| SCHEMBL15888924 | 0.76 | TNKS2 (0.34) | ADORA3ADORA2AADORA1GSK3BTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588482-B1 | PREPARATION OF TESETAXEL AND RELATED COMPOUNDS AND CORRESPONDING SYNTHESIS INTERMEDIATE | ODONATE THERAPEUTICS LLC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20160376284-A1 | TAXANE COMPOUNDS, COMPOSITIONS AND METHODS | ODONATE THERAPEUTICS, LLC | 2016-12-29 | — | — | US | disclosed |
| US-9434740-B2 | Taxane compounds, compositions and methods | ODONATE THERAPEUTICS, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-9284327-B2 | Taxane compounds, compositions and methods | GFV, LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150080578-A1 | Taxane Compounds, Compositions and Methods | ODONATE THERAPEUTICS, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20140249186-A1 | TAXANE COMPOUNDS, COMPOSITIONS AND METHODS | GFV, LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8785669-B2 | Taxane compounds, compositions and methods | GFV, LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-8697892-B2 | Taxane compounds, compositions and methods | GFV, LLC (US) | 2014-04-15 | — | — | US | disclosed |
| WO-2013162922-A1 | TAXANE COMPOUNDS, COMPOSITIONS AND METHODS | GENTA INCORPORATED (US) | 2013-10-31 | — | — | WO | disclosed |
| EP-2588482-A1 | PREPARATION OF TESETAXEL AND RELATED COMPOUNDS AND CORRESPONDING SYNTHESIS INTERMEDIATE | Genta Incorporated (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120220634-A1 | Taxane Compounds, Compositions And Methods | GENTA INCORPORATED (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120004429-A1 | Taxane Compounds, Compositions And Methods | GENTA INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2012003199-A1 | PREPARATION OF TESETAXEL AND RELATED COMPOUNDS AND CORRESPONDING SYNTHESIS INTERMEDIATE | GENTA INCORPORATED (US) | 2012-01-05 | — | — | WO | disclosed |
| US-6677456-B2 | AS ANTITUMOR COMPOUND; CAN BE ORALLY ADMINISTERED | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20020143178-A1 | Pentacyclic taxan compound | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249186-A1 | TAXANE COMPOUNDS, COMPOSITIONS AND METHODS | TOP2A, TOP1, TOP2B | ADORA3 1180/4885ADORA2A 560/4885ADORA1 1268/4885 |
| US-20160376284-A1 | TAXANE COMPOUNDS, COMPOSITIONS AND METHODS | TOP2A, TOP1, TOP2B | ADORA3 1180/4885ADORA2A 560/4885ADORA1 1268/4885 |
| US-20150080578-A1 | Taxane Compounds, Compositions and Methods | TOP2A, TOP1, TOP2B | ADORA3 1180/4885ADORA2A 560/4885ADORA1 1268/4885 |
| US-20120004429-A1 | Taxane Compounds, Compositions And Methods | TOP2A, TOP1, TOP2B | ADORA3 1180/4885ADORA2A 560/4885ADORA1 1268/4885 |
| US-20020143178-A1 | Pentacyclic taxan compound | TUBB6, TUBB1, TUBA1A | ADORA3 3304/4885ADORA2A 2376/4885ADORA1 2270/4885 |
| US-20120220634-A1 | Taxane Compounds, Compositions And Methods | TOP2A, TOP1, TOP2B | ADORA3 1180/4885ADORA2A 560/4885ADORA1 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.